Maximize the Clinical & Commercial Opportunity of the Adenosine-Pathway as a Second-Generation Immuno-Oncology Target

A plethora of showstopping clinical trial data readouts are being met with refreshed excitement, enthusiasm and R&D investment for adenosine-pathway targets, one of the most validated and established oncology pathways.

As such, the inaugural Adenosine-Pathway Targeted Cancer Immunotherapy Summit has arrived as the definitive conference dedicated to optimizing efficacy of adenosine-pathway targeted drugs, overcoming challenges of resistance and immunosuppression and supercharging therapeutics into the clinic.

Uniting experts in adenosine, immune checkpoint, tumor microenvironment, immune-oncology and second-generation IO, don’t miss your chance to investigate adenosine signaling in the context of the hypoxic tumor microenvironment to inform clinical advances, leverage biomarkers to evaluate disease and identify patient responders for Adenosine-Pathway therapeutics.

Join fellow pioneers in the field to explore preclinical model landscapes and gain a deeper understanding of the rationale of combination therapies to enhance treatment potency & efficacy.

Don’t miss your chance to solve these challenges and maximize the clinical and commercial opportunity of the adenosine-pathway.

2022 World-Class Speaker Faculty Included:

Proud To Partner With

Health & Safety

The health, safety and well-being of our community remains our highest priority, therefore, all attendees will be required to complete a health declaration prior to attending the event, as well as comply with the City of Boston’s B Together policy. This policy requires individuals to show you proof of vaccination against COVID-19 in order to gain admittance to the conference venue. For further information around Health and Safety onsite, please visit our FAQs page here or for more information on the B Together Policy, please see here.

* Please note, this is subject to change at any time without prior notice.